We have investigated the effect of growth hormone (GH) treatment on GH receptor mRNA expression in five prepubertal children with Prader-Willi syndrome and in eight patients with GH deficiency. An adipose tissue needle biopsy was taken before and after 2-4 mo of GH treatment, and RNA was isolated from adipose tissue and from adipocytes. GH receptor mRNA levels were determined by an RNase protection/solution hybridization assay. To further assess the specificity of the assay for GH receptor mRNAs, RNA extracted from human adipose tissue was subjected to Northern blot analysis. GH treatment significantly
Abbreviations GH, growth hormone hGHR, human GH receptor PWS, Prader-Willi syndrome TCA, trichloroacetic acid regarding the effects of GH treatment on GH receptor expression in man.
The aim of the present study was to evaluate the effects of GH treatment on GH receptor mRNA expression in adipose tissue obtained from children with PWS and patients with GH deficiency.
METHODS
Five prepubertal children with PWS, three children and six adults with GH deficiency were studied. Children were treated with 0.1 U of GH per kg/d. The adults were treated with 0.03 U of GH per Kgid. An abdominal adipose tissue needle biopsy (1-2 g) was taken before the initiation of treatment and after 2-4 mo of treatment. The last GH injection was given 14 h before the second biopsy. All biopsies were obtained between 0830 and 0930 h after an overnight fast. The biopsy was taken after Citanest analgesia in the surrounding area. In three children with PWS, part of the adipose tissue was used to prepare adipocytes. The adipocytes were isolated mainly using Rodbell's method (11) . The adipocytes were washed in KrebsRinger phosphate albumin buffer and aggregated material was removed by filtration through a silk cloth. For Northern blots and RNase protection assay, the adipose tissue samples were taken from healthy young adults and adipose tissue was pooled from five children 3-6 y of age during inguinal hernia operations. The study was approved by the Ethics Committee of Karolinska Institute.
Preparation of RNA and Northern blot analysis. Total tissue and cellular RNA were extracted as previously described (12) . Northern blot analysis was performed, as previously described (13) . Briefly, hybridization was carried out for 48 h at 55°C in a solution containing 50% formamide, 5 X SSC, 5 X Denhardt's solution, 5 mmol/L phosphate buffer, pH 6.5, 5 mmol/L EDTA, 0.1% SDS, and 200 p g of salmon testis DNA, and the addition of 4-6 X 1 0 %~m / m l 32~-labeled cRNA GH receptor probe. Oligonucleotide probes (50 bp) were cloned into the BamHIISalI sites in pGEM+4Z (Promega Biotech). The sequence of these inserts in pGEM+4Z was confirmed by DNA sequencing. For the GH probe, the sequence of the oligonucleotide used corresponded to nucleotides 721-771 in the hGHR gene (14) .
Solution hybridization analysis of RNA. For measurement of specific mRNA levels, complementary RNA (cRNA) probes were synthesized in vitro as described before, and radiolabeled with 3 5~-~~~ (Arnersham, Sweden), using reagents supplied by Promega Biotech (Madison, WI). The solution hybridization assay was carried out as previously described (15) . Briefly, the hybridization signal of a sample was compared with a standard curve constructed from incubations with a known amounts of sample. RNA was calculated from the linear part of the respective standard curve. Results are expressed as am01 mRNA per k g total RNA calculated from the standard curve and spectrophotometric measurements. Each standard and RNA sample was analyzed in duplicate.
y-actin probe was synthesized in vitro and radiolabeled with 3 5~-~~~ as described above (16) . The expression of the y-actin gene was used as an internal control.
Results are expressed as means ? SD. Differences between the groups were assessed using the paired t test. p values of less than 0.05 were considered to be significant.
RNase protection assay. The specificity of the solution hybridization method was tested by an RNase protection assay with 100 pg of hGHR-specific sense nucleotide described above and RNA extracts from normal adipose tissue specimens. The RNA extracted was hybridized with labeled sense under conditions identical to those described above. After RNase treatment, extraction with phenol/chloroform and ethanol precipitation, RNA was size-separated by electrophoresis through a denaturating 4% polyacrylamide gel. Then, the gel was dried and the hybridized probe detected by autoradiography for 24 h. An RNA ladder was used as a marker.
RESULTS
RNase protection assay and Northern blot analysis. The specificity of cRNA probes used in the present study was evaluated with RNase protection assay. The GH receptor probe corresponds to the intracellular domain of the GH receptor (13) and it showed no nonspecific hybridization, as indicated by a single discrete band of the RNase-protected products on the gel. As shown in Fig. 1 after hybridization with human adipose tissue RNA had a mobility on SDS gel similar to the 50 nucleotides long GH receptor-specific probe. To further assess the specificity of the assay for GH receptor mRNAs, RNA extracted from human adipose tissue was subjected to Northern blot analysis. The GH receptor probe detected a band of approximately 3.9 kb in adipose tissue of both children and adults (Fig. 1) .
Quanti$cation of GH receptor mRNA. The GH receptor mRNA was measured before and during GH treatment of children with PWS and patients with GH deficiency. To obtain an estimate of the level of GH receptor mRNA an RNase protection/solution hybridization technique was used. Identical cRNA probe was used as in RNase protection described above but instead of analysis of RNase resistant hybrids on SDS gel the hybrid formation was determined by TCA precipitation and liquid scintillation counting. The GH receptor mRNA levels in adipose tissue were found to be higher in children with PWS after 2-4 Ino of GH treatment than the pretreatment expression levels (p < 0.02) (Fig. 2) . Furthermore, the GH receptor mRNA levels in adipose tissue from all patients with GH deficiency were higher after 2-4 mo of GH treatment than the pretreatment expression levels ( p < 0.02) (Fig. 3) .
In three PWS subjects, GH mRNA levels were measured in adipose tissue and in isolated adipocytes. The mRNA levels were higher in adipose tissue than in adipocytes. However, the same increase in GH receptor mRNA levels during GH treatment was observed also in the adipocytes (Fig. 2) .
The y-actin mRNA levels in adipocytes and in adipose tissue of children with PWS and in GH-deficient patients were not affected by GH treatment (Table 1) .
DISCUSSION
In the present study, the regulatory effect of GH on GH receptor mRNA expression in human adipose tissue has been investigated. Thc presence of the GH receptor mRNA in human adipose tissue and the specificity of the probe used were confirmed by RNase protection assay and Northern blot, using material from healthy children and adults. A single discrete band of the RNase protected products on SDS gels mediated a specific hybrid formation using RNase protection/solution hybridization assay. Alternatively, using Northern blot, a band of 3.9 kb was detected which is in accordance with what previously has been demonstrated in other human tissues (13) . Two isoforms of hGHR mRNA, one containing exon 3 (encoding an extracellular domain of the receptor), hGHR, and one exclud- Adipose tissue and adipocytes were obtained from children with PWS, and patients with GH deficiency, as described in Methods, before (A), and after 2-4 mo of GH treatment (B). y-Actin n?RNA levels are expressed as amol n~RNAlpg total RNA.
-NS = not significant. ing exon 3, hGHRd3, have been described (14) . The GH receptor probe used corresponds to the intracellular domain of the GH receptor (13) . Thus, our results regarding the levels of GH receptor mRNA were affected neither by the alternative splicing of the GH receptor nor by a putative expression of GH binding protein. GH receptor mRNA expression was significantly higher in adipose tissue of PWS children after 2-4 mo of GH treatment. The same pattern was observed in GHdeficient patients, the GH receptor mRNA levels being significantly higher in adipose tissue from GH-deficient children and GH-deficient adults during treatment. The GH receptor is expressed in adipocytes and in other cell types in adipose tissue, such as fibroblasts (17) . Amounts of adipose tissue sufficient for simultaneous studies of intact adipose tissue and fat cells were obtained from only three subjects with PWS. The GH receptor mRNA levels were higher in adipose tissue than in isolated adipocytes, which indicate that GH receptor mRNA from other cell types considerably affected the measurements in adipose tissue. However, the relative increase was the same in adipocytes and in the adipose tissue, which indicates that GH receptors in both adipocytes and stromal cells mRNA are up-regulated by GH.
The expression of the y-actin gene is reported to be stable in various cell types and not influenced by hormone levels, such as GH, glucocorticoids or thyroxine (16) .
In the present study, the y-actin gene mRNA levels in adipocytes and adipose tissue were not affected by GH treatment, indicating a specific increase in GH receptor mRNA. Our results agree with data obtained in rats. In adipocytes from hypophysectomized rats, the specific GH binding was 25% of the binding observed in adipocytes of normal rats. Administration of bovine GH for 5 d increased GH binding approximately 2-fold, compared with controls (18) . Furthermore, in vitro studies of isolated fat cells from normal rat show a 75% increase in GH receptors after preincubation with GH (19) . In contrast to the prolonged effects of GH, a single injection of GH greatly reduces both total and free liver GH receptors in rats (20) .
Treatment with GH markedly affects the general metabolism in adults as regards the adipose tissue. This effect of GH on adipocytes is probably direct rather than mediated via IGF-I, because no IGF-I receptors are present in mature adipocytes (21) . It has been shown that the dose of GH can be reduced after 1 or 2 mo of treatment, without any negative effects on IGF-I levels or other metabolic parameters (22) . This phenomenon may partly be explained by the up-regulation of the GH receptor that could sensitize tissues to GH.
